ATP9A

Across TCGA pan-cancer cohorts, ATP9A RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of ATP9A’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ATP9A RNA is repressed in tumor relative to normal tissue. In most cancer types ATP9A is over-expressed in tumor, although a few such as KIRC and THCA show the opposite, repressed pattern.

KIRC, LIHC, and KIRP are the cancer types where ATP9A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATP9A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−1.090	<.001	11	view →
LIHC	Female	II,III,IV	+1.671	<.001	8	view →
KIRP	All	II,III,IV	+0.994	.003	7	view →
STAD	Male	II,III,IV	+1.019	.004	6	view →
THCA	All	All	−0.437	.002	6	view →
CHOL	Male	All	+2.761	<.001	5	view →
BRCA	All	All	−0.343	<.001	4	view →
LUAD	All	All	+0.340	.008	3	view →
UCEC	All	All	−0.570	.012	2	view →
COAD	All	All	+0.414	.029	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

ATP9A–KIRC

Open the KIRC breakdown →